Replies to post #357893 on Elite Pharmaceuticals Inc (ELTP)

[kayak_wench]

We'll the number for the market for Adderall XR you provided (223 million) would put Elite around 8% market penetration, which is good. But $223 million is much much less than the number of over $1.3 billion provided in the table in the IHUB web page for Elite. Interestingly hte Concerta number in your table is also much lower. Looks like Vyvanse is taking numbers down quickly. It sure would be nice if Elite is getting a head start on having a formulation ready to go when the Vyvanse patent expires.

[The ELTP King]

These numbers are WAY off in the image below.

Not sure about the other two products.


*ACTUAL* IQVIA Market Size:

Adderall XR: $1,488,100,000 (As of May 2020)

Concerta: $1,159,000,000 (As of June 2020)


COMPLETELY wrong numbers shown below for at least Adderall XR and Concerta:

[The ELTP King]

Thanks.

Drug patent watch said that by analyzing the patents and regulatory protections for Vyvanse, it appears that the earliest date for generic entry will be February 24, 2023.